2020
DOI: 10.1080/08998280.2020.1772029
|View full text |Cite
|
Sign up to set email alerts
|

Nasal angiomyolipoma causing persistent nasal congestion

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 8 publications
0
2
0
Order By: Relevance
“…Only 5 similar cases had previously been reported. [1][2][3][4][5] Angiomyolipoma represents a part of the group of perivascular epithelioid cell tumors (PEComas) including histologically similar lesions occurring in a variety of cutaneous, visceral, and soft tissue sites. 6 Although angiomyolipoma is a benign lesion, there is evidence in the literature of malignant transformation of angiomyolipoma primarily localized in the kidney and liver.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Only 5 similar cases had previously been reported. [1][2][3][4][5] Angiomyolipoma represents a part of the group of perivascular epithelioid cell tumors (PEComas) including histologically similar lesions occurring in a variety of cutaneous, visceral, and soft tissue sites. 6 Although angiomyolipoma is a benign lesion, there is evidence in the literature of malignant transformation of angiomyolipoma primarily localized in the kidney and liver.…”
Section: Discussionmentioning
confidence: 99%
“…9,10 About 80% of patients with nasal angiomyolipoma are male and between 29 and 88 years of age. [1][2][3][4][5] Watanabe and Suzuki proposed the classification of angiomyolipomas into 2 clinicopathological types: the mucocutaneous type, originating from the skin, nasal cavity, oropharynx, and larynx, and the hepatorenal (PEComatous) type. 11 Histopathologically, the mucocutaneous type is composed of spindled and mature smooth muscle cells, has no epithelioid morphology, and, as was the case with our patient's tumor demonstrates no immunoreactivity to the melanocytic marker HMB-45.…”
Section: Discussionmentioning
confidence: 99%